Journal of Immunotoxicology, 2012; Early Online: 1–9
© 2012 Informa Healthcare USA, Inc.
ISSN 1547-691X print/ISSN 1547-6901 online
DOI: 10.3109/1547691X.2012.732121
RESEARCH ARTICLE
Journal of Immunotoxicology Downloaded from informahealthcare.com by Dr Chukwuemeka S. Nworu on 10/27/12
For personal use only.
Extracts of Ficus exasperata leaf inhibit topical and systemic
inflammation in rodents and suppress LPS-induced
expression of mediators of inflammation in macrophages
Chukwuemeka S. Nworu1, Henry C. Nwuke1, Peter A. Akah1, Festus B.C. Okoye2,3, and
Charles O. Esimone4
Department of Pharmacology and Toxicology, Faculty of Pharmaceutical Sciences, University of Nigeria, Nsukka,
Nigeria, 2Institute of Pharmaceutical Biology and Biotechnology, Heinrich-Heine University, Düsseldorf, Germany,
3
Department of Pharmaceutical and Medicinal Chemistry, and 4Department of Pharmaceutical Microbiology and
Biotechnology, Faculty of Pharmaceutical Sciences, Nnamdi Azikiwe University, Awka, Nigeria
1
Abstract
The leaves of Ficus exasperata are mashed and prepared as poultices that are placed on swellings, wounds, and arthritic
joints to relieve swelling and pains by the Igede tribal community of Nigeria. The leaf and stalk are also squeezed and
used to mitigate itching or inflammation. These claimed benefits inspired this study in which topical and systemic
(acute, chronic) anti-inflammatory activities of a methanol/methylene chloride leaf extract of F. exasperata (MFE)
were assessed in rodents. Effects of an aqueous leaf extract (AFE) on lipopolysaccharide-induced expression of
interleukin-1β (IL-1β), tumor necrosis factor (TNF)-α, and inducible nitric oxide (iNO) were also investigated in murine
bone marrow-derived macrophage (BMDM) cultures. Treatment of rats with MFE (200 and 400 mg/kg) led to significant
inhibition of acute and chronic inflammation induced by, respectively, agar and formaldehyde in the paws. Topically,
pre-application of mice with MFE (5 µg/ear) also significantly inhibited (by up to 21%) ear edema induced by xylene.
In vitro, pre-treatment of BMDM with 5–100 µg AFE/ml significantly inhibited IL-1β, TNFα, and iNO production in a
dose-related manner. BMDM viability was not significantly affected AFE at concentrations up to 200 µg/ml. Initial
studies showed that flavonoids, alkaloids, and terpenoids were the predominant phytoconstituents in each extract. In
conclusion, the results of the various investigations indicated that F. exasperata leaf extracts possess anti-inflammatory
properties that could underlie the benefits associated with the folklore use of the plant. The results also show that the
extracts may be acting through a suppression of mediators of inflammation, such as IL-1β, TNFα, and iNO.
Keywords: Arthritis, chronic inflammation, Ficus exasperata, inflammatory mediators, macrophages, paw edema
Introduction
activation, inflammatory mediators, fluid extravasation,
cell migration, tissue breakdown, and repair (Vane and
Bolting, 1995; Perianayagam et al., 2006).
Many human and animal diseases, such as arthritic
disorders, lupus erythematosus, asthma, bronchitis,
inflammatory bowel disease, ulcerative colitis,
pancreatitis, hepatitis, cancer, and infections possess
an inflammatory component. Conventional drug
treatments are limited in their effectiveness in managing
the incidence/outcome of many inflammatory diseases.
They also present a significant number of side-effects.
Inflammation is a complex and dynamic biological
response that is elicited in response to harmful stimuli,
such as pathogens, mechanical injuries, burns, irritants, and other noxious stimuli that may threaten the
well-being of the host. Inflammation is marked by local
response to cellular injury that is associated with capillary dilatation, leucocytes infiltration, redness, heat, pain,
swelling, and often loss of function that serves to initiate mechanisms of eliminating the noxious agents and
damaged tissues. It involves a complex array of enzyme
Address for Correspondence: Chukwuemeka S. Nworu, Department of Pharmacology & Toxicology, Faculty of Pharmaceutical Sciences,
University of Nigeria, Nsukka, 410001, Enugu State, Nigeria; E-mail: csnworu@yahoo.com
(Received 02 August 2012; revised 31 August 2012; accepted 17 September 2012)
1
Journal of Immunotoxicology Downloaded from informahealthcare.com by Dr Chukwuemeka S. Nworu on 10/27/12
For personal use only.
2
C. S. Nworu et al.
Recently, it has been shown that non-steroidal antiinflammatory agents may even slow down the healing
process in many diseases (Ayoola et al., 2009). Despite
progress made in use of orthodox medicines for
treatment of inflammatory states, there are still needs
for effective, affordable, improved remedies devoid of
gastro-erosive side-effects or other unwanted effects
associated with steroidal anti-inflammatory therapy.
In this regards, medicinal plants and herbal remedies
have been employed in Complementary and Alternative
Medicine (CAM) for the treatment of inflammation
and disorders having inflammatory components. The
treatment of inflammation and rheumatic disorder is an
area in which the practitioners of traditional medicine
enjoy patronage and success (Akah and Nwambie,
1994). Taking into account that many important
anti-inflammatory prototypes (e.g., salicylates) were
originally derived from plants, the study of plant species
traditionally used as anti-inflammatory agents is still
seen as a fruitful strategy in the search of new antiinflammatory drugs.
The plant Ficus exasperata (Moracea) is a medicinal
plant used in folk medicine to treat inflammation/inflammatory disorders by the Igede people of Benue state,
Nigeria (Igoli et al., 2005). Use of this plant has produced
claims of effectiveness in resolving topical inflammatory
events and systemic rheumatic disorders. The leaves of
F. exasperata are mashed and prepared as poultices that
are placed on swellings, wounds, and arthritic joints to
relieve swelling; the leaf and stalk are used to mitigate
itching/inflammation as well. The use of F. exasperate
leaves and roots in the treatment of high blood pressure,
asthma, dyspnea, rheumatism, arthritis, intestinal pain,
colic, epilepsy, bleeding, and wounds in African traditional
medicine was well documented over a 40-year period (see
Irvine, 1961 up through Chhabra et al., 1990). Several studies have validated some of these traditional uses in model
systems. For example, Akah et al. (1997, 1998) reported
significant anti-ulcer and anti-motility effects of a methanol F. exasperata leaf extract in rats. Ayinde et al. (2007)
demonstrated that the aqueous leaf extract of F. exasperata
caused a dose-related reduction in mean arterial blood
pressure; this effect was also blocked by anti-histamine
and -muscarinic agents. Recently, it was reported that the
hydroalcoholic leaf extract of F. exasperata displayed antinociceptive and weak anti-pyretic properties and inhibited
carrageenan-induced footpad edema in chicks (Woode
et al., 2009). In another related study, the ethanol extract of
these leaves was shown to possess anti-oxidant and antiarthritic properties (Abotsi et al., 2010).
To establish a scientific basis (if any) for these
traditional practices and to understand possible
mechanism(s) by which these extracts may act, a study
was designed to investigate the topical and systemic
(acute and chronic) anti-inflammatory properties of
F. exasperata leaf extracts in rodent models. Effects of the
extracts on inducible expression of mediators of inflammation by murine macrophages were also assessed.
Materials and methods
Collection and extraction of plant material
Fresh leaves of Ficus exasperata were collected in
March 2009 from Nsukka, Enugu State, Nigeria and
authenticated by Mr Alfred Ozioko of the Bioresources
Development and Conservation Program (BDCP)
Centre, Nsukka. The leaves were cleaned, shade-dried,
and pulverized to coarse powder using a laboratory-scale
slow speed electric blender. A portion of the powdered
aerial parts (2 kg) was exhaustively extracted with a 1:1
mixture of methylene chloride and methanol by continuous cold maceration for 48 h with intermittent agitation.
The extract solution was then filtered through Whatman
No. 1 filter paper and concentrated by evaporation
in vacuo to obtain a dried extract (MFE; 3.14% [w/w]
recovery). The aqueous leaf extract of Ficus exasperata
(AFE) used for in vitro cell culture experiments was
obtained by macerating 250 g of the leaf powder for 2 h
in 400 ml warm sterile distilled water, with intermittent
agitation. The extract was then filtered and lyophilized to
yield a dried extract (AFE; 8.27% [w/w] recovery). Both
extracts were aliquoted and stored at −20°C until used for
experiments. The endotoxin level in a 1 mg/ml solution of
AFE was determined using a Limulus Amoebocyte Lysate
kit (LAL; Endosafe®; Charles River, Sulzfeld, Germany).
The results showed that the level of any endotoxin present in the extract was below detection (< 0.03 EU).
Animals
Adult Wistar rats (150–250 g) and Swiss mice (15–25 g)
of both sexes were obtained from the Laboratory
Animal Facility of the Department of Pharmacology and
Toxicology, Faculty of Pharmaceutical Sciences, University
of Nigeria, Nsukka (UNN). Balb/c mice (20–25 g), obtained
from Centre d’Elevage (Janvier, France), were used for the
in vitro studies. The animals were housed in institutional
facilities under standard conditions (25 ± 2°C and a 12-h
light/dark cycle) and provided access to standard pellets
and drinking water ad libitum. Use and care of the animals
in this study were in accordance with ethical guidelines as
contained in the European Convention for the Protection
of Vertebrate Animals used for Experimental and Other
Scientific Purposes (EEC Directive 86/609/EEC) of 1986.
Prior to use in the different experiments, the animals were
allowed at least 5 days to acclimatize.
Preliminary phytochemical tests
Preliminary phytochemical tests were carried out on
the extracts using standard procedures previously
described (Evans, 1998; Harborne and Harborne, 1998).
Phytochemical tests were conducted on MFE and AFE
for the presence of flavonoids, alkaloids, sterols, triterpenoids, saponins, glycosides, and tannin.
Acute toxicity (LD50) test
The acute toxicity (LD50) of the methanol/methylene
chloride extract of F. exasperata (MFE) was estimated in
Journal of Immunotoxicology
Journal of Immunotoxicology Downloaded from informahealthcare.com by Dr Chukwuemeka S. Nworu on 10/27/12
For personal use only.
Anti-inflammatory mechanisms of F. exasperata leaf extracts 3
mice by oral and intra-peritoneal routes of administration
using the method described by Lorke (1983). Briefly, the
tests involved two phases. The first involved the determination of the toxic range. The mice were placed in three
groups (n = 3/group) and MFE (10, 100, or 1000 mg/kg)
was administered either intraperitoneally (IP) or per os.
The injection and gavage volumes were always 200 µl. The
treated mice were then observed for 24 h for mortality.
Mortality in the first phase determined the four different
doses of MFE administered (IP or per os) in the second
phase. After treatment, the animals were observed for
lethality/signs of acute intoxication for the next 24 h. The
LD50 was calculated as the geometric mean of the highest
non-lethal dose and the least toxic dose.
Effect of MFE on acute inflammation in mouse ear
induced by xylene
The effect of MFE on acute topical inflammation was
evaluated using earlier described methods (Tubaro et al.,
1985; Gad et al., 1987; Atta and Alkohafi, 1998). For each
experiment, Swiss mice of either sex were divided into
three groups (n = 8/group). The treatment groups received
MFE extract (5 mg/ear; applied in 50 µl 2% Tween)
applied to the anterior surface of the right ear. Topical
inflammation was instantly induced on the posterior surface of the same ear by application of xylene (30 µl/ear).
Negative and positive control mice received 2% Tween
and indomethacin (5 mg/ear; applied in 50 µl 2% Tween),
respectively. Two hours after induction of inflammation,
mice were euthanized by ether anesthesia and both ears
were removed. Circular sections (4 mm diameter) of both
the right (treated) and left (untreated) ears were isolated
using a cork borer and weighed. Edema was quantified as the weight difference between each plug. Antiinflammatory activity was evaluated as per cent edema
reduction/inhibition in the treated animals relative to the
edema in control hosts (Tubaro et al., 1985; Asuzu et al.,
1999) using the formula: % inhibition/reduction = 100 ×
(1 − {[Rt – Lt]/[Rc – Lc]}) where; Rt = treated animal right ear
plug mean weight; Lt = treated animal left ear plug mean
weight; Rc = control animal right ear plug mean weight;
and Lc = control animal left ear plug mean weight.
Effect of MFE on agar-induced acute paw edema in rat
The effect of MFE on rat paw edema was assessed by
the method of Winter et al. (1962). Acute inflammation
was measured in terms of change in volume of the rat
hind paw (Backhouse et al., 1996) induced by injection
of agar. Rats were randomized into four groups of five
animals each. The treatment groups received MFE (200
or 400 mg/kg; orally) while the negative and positive control groups were given equivalent volume of the vehicle
(distilled water in 2% Tween) or diclofenac (50 mg/kg),
respectively. One hour after the treatments, edema was
induced in the right hind paws of the rats by sub-plantar
injection of an agar suspension (2% [w/v]; 100 µl/footpad) as the phlogistic agent. Edema in the treated paw
was measured by the volume of distilled water displaced
by each paw before and 1, 2, 3, 4, and 5 h after induction
of edema. Measurement of rat paw edema followed the
previously reported procedure of Fereidoni et al. (2000).
Inflammation was assessed as the difference between
the paw volume at zero time of the treated paw (Vo) and
the paw volume at the various time intervals (Vt) after the
administration of the phlogistic agent. Percentage inhibition of edema was calculated using the relation (Ahmed
et al., 1993; Perez et al., 1996): % inhibition = 100 × (1 − {[a
– x]/[b – y]}) where; a = mean paw volume of treated rats
at various times after agar injection; x = mean paw volume of treated rats before agar injection; b = mean paw
volume of control rats at various time after agar injection;
and y = mean paw volume of control rats before agars
injection.
Effect of MFE on formaldehyde-induced arthritis in
rats
The effect of MFE on chronic inflammation was assessed
using the model of rat arthritis induced by formaldehyde described by Selye (1949). Here, rats of either
sex were randomized into four groups (n = 5) for the
study. The first two groups were treated with MFE (200
or 400 mg/kg; per os); the negative controls received
(per os) an equivalent volume of vehicle (2% Tween)
or indomethacin (50 mg/kg). Arthritis was induced 1 h
after the various treatments on the first and third day
by sub-plantar injection of 100 µl of a 2.5% formaldehyde solution. Arthritis was assessed by measuring the
volume of distilled water displaced by the paw before
arthritis induction and once daily for 10 days, starting
from the day after induction. Treatments with MFE and
the controls continued once daily for 10 days. Global
edematous responses were quantified as the area
under the curve (AUC; calculated using trapezoidal
rule) of the time-course of the arthritic event. The level
of inhibition of arthritis was calculated using: % inhibition = 100 × (1 − {AUCt]/[AUCc]}), where AUCc = AUC of
control; AUCt = AUC of treated hosts.
Isolation and culture of bone marrow-derived
macrophages (BMDM)
Murine BMDM were generated from BM cells of the tibia,
humerus, and femur of BALB/c donor mice using methods previously described (Lin et al., 2001; Weischenfeldt
and Porse, 2008). BM cells were harvested and cultured
in monocytic cell culture medium containing RPMI
1640 medium (Gibco, Karlsruhe, Germany) supplemented with 5% heat-inactivated fetal calf serum (FCS),
50 µM 2-mercaptoethanol (Gibco), 1% L-glutamine,
1% non-essential amino acids, 1 mM pyruvate, 100 U
penicillin/ml, 100 µg streptomycin/ml, and 10 ng/ml
recombinant murine colony-stimulating factor (rmCSF1; Immunotools, Friesoythe, Germany) in T-75 culture
flasks. The cells were incubated at 37°C and 5% CO2 for
24 h to adhere and allow for removal of stromal cells and
mature BM resident macrophages. Non-adherent cells,
which are mainly progenitor cells, were recovered after
© 2012 Informa Healthcare USA, Inc.
4
C. S. Nworu et al.
24 h of incubation and further incubated in culture flasks
to expand and differentiate the cells under the influence
of the rmCSF-1. After 7 days of culture, non-adherent
cells were removed and the adherent cells were washed
and harvested using a cell scraper. Viability of the cells
(macrophages) was assessed by trypan blue exclusion.
The BMDM generated were plated and used for the
in vitro studies of the effects of AFE on inducible NO and
pro-inflammatory cytokine production.
Journal of Immunotoxicology Downloaded from informahealthcare.com by Dr Chukwuemeka S. Nworu on 10/27/12
For personal use only.
Viability of AFE-treated BMDM assessed using
an MTT assay
The viability of the BMDM after treatment with AFE
extract was determined using cellular respiration as
an indicator. Cell viability was determined on the
basis of mitochondrial-dependent reduction of MTT
(3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide) to formazan (Mosmann, 1983). BMDM were
cultivated in 96-well plates (1 × 105 cells/well) for 24 h.
The cells were then treated with various concentrations
(0, 5, 25, or 100 µg/ml) of AFE in a 100 µl volume. After
24 h of incubation at 37°C, the medium in each well
was discarded; the cells were then incubated with fresh
medium containing 5 mg MTT/ml for 4 h. The formazan
that formed in the cells was then dissolved by addition of
150 µl dimethyl sulfoxide to each well (for 10 min at 37°C)
and the optical density of the solution in the well was
measured at 550 nm in a microtiter plate reader (Tecan,
Grödig, Austria).
Effect of AFE on the expression of LPS-induced nitric
oxide (iNO) by BMDM
BMDM were cultivated in 48-well plates (5 × 105
cells/well) at 37°C in a 5% CO2 incubator for 24 h.
Thereafter, the cells were then pre-treated with graded
concentrations of AFE (0, 5, 25, or 100 µg/ml) and incubated for 2 h. The culture medium was then removed and
replaced with fresh medium and the cells then treated
with 10 µg/ml of LPS (lipopolysaccharide; serotype
0128:B12; Sigma, Munich, Germany) or culture medium
(as control). Conditioned supernatants were collected
after 24 h of incubation and stored at −80°C. Nitrite levels
in the supernatant were measured in 96-well microtiter
plates by mixing 100 µl of cell-free culture supernatant
with an equal volume of Griess reagent (0.1% naphthylethylenediamine dihydro-chloride and 1% sulphanilamide
in 5% phosphoric acid; Applichem, Darmstadt, Germany)
and then incubating at room temperature for 10 min. The
NO concentration was then determined at 550 nm in the
plate reader by extrapolation from a standard curve generated using NaNO2 standards that had been included in
each measurement plate.
Effect of AFE on expression of inducible
pro-inflammatory cytokine secretion
BMDM (5 × 105 cells/well) was seeded in 48-well plates
and cultured for 24 h. Thereafter the cells were pretreated with graded concentrations of AFE (0, 5, 25, or
100 µg/ml) and incubated for 2 h. The culture medium
was then removed and replaced with fresh medium
and the cells then treated with 10 µg LPS/ml or culture
medium (control). After 24 h of incubation at 37°C, the
conditioned culture medium in each well was collected
and stored at −80°C. Concentrations of interleukin-1β
(IL-1β) and tumor necrosis factor (TNF)-α in the harvested supernatants were determined using commercial
ELISA kits (PeproTech, Hamburg, Germany). The sensitivity of the IL-1β and TNFα kits were, respectively, 0.063
and 0.016 ng/ml.
Statistical analysis
Results are presented as mean and standard error of
the mean (SEM) of at least triplicate determinations for
in vitro experiments and a group size of five for in vivo
experiments. To demonstrate statistical significance of
data, a one-way Analysis of Variance (ANOVA) using
Prism5 software (GraphPad Software, Inc., San Diego,
CA) was performed. Generally, differences between test
and control treatments or between any paired treatments
of groups were assigned significance at p < 0.05.
Results
Extraction of plant material and phytochemistry
studies
The extraction process yielded 62.80 g (3.14% [w/w]) of
methylene chloride/methanol extract of F. exasperata
(MFE). The aqueous extraction of F. exasperata yielded
20.68 g (8.27% [w/w]) of extract (AFE). Preliminary phytochemical analysis showed the presence of alkaloids, flavonoids, resins, carbohydrate, proteins, oil, and terpenoids
in the MFE (Table 1). The AFE tested positive for glycoside,
saponins, alkaloids, flavonoids, resins, carbohydrate, proteins, acidic compounds, and terpenoids (Table 1).
Acute toxicity test
An acute toxicity test carried out on the MFE (using oral
and intraperitoneal routes) showed there were no deaths
and no observable signs of acute intoxication in the mice
after a 24 h observation in the two stages of the study.
Thus, the LD50 of the test extract was set at > 5 g/kg body
weight (Lorke, 1983) in mice for either route.
Effect of MFE on topical (acute) inflammation
The MFE significantly inhibited xylene-induced ear
edema in mice (Table 2). Mice treated with MFE had
a mean ear edema of 7.88 ± 1.46 mg; this represented a
21.2% inhibition of inflammation from a 10.00 ± 1.65 mg
level for the untreated group. Indomethacin (used as
standard anti-inflammatory agent) produced mean
ear edema of 4.92 ± 1.03 mg, representing a 50.8%
inhibition) (Table 2).
Effect of MFE on acute inflammation in rats
Pre-treatment of rats with the MFE caused significant
inhibition of agar-induced inflammation and a more
Journal of Immunotoxicology
Anti-inflammatory mechanisms of F. exasperata leaf extracts 5
rapid resolution of paw edema over a 5-h period of measure (Figure 1). Edema was always greater in control
rats at every timepoint compared to in rats treated with
extract. Rats that had received 200 or 400 mg MFE/kg
had only 0.28 ± 0.02 and 0.32 ± 0.04 cm3 mean paw edema
values, respectively, after 1 h, while negative controls had
a value of 0.42 ± 0.04 cm3 at that time. In general, both
MFE treatments resulted in inhibited edema formation
at each of the measured timepoints (Figure 1).
Journal of Immunotoxicology Downloaded from informahealthcare.com by Dr Chukwuemeka S. Nworu on 10/27/12
For personal use only.
Effect of MFE on formaldehyde-induced arthritis
Anti‐arthritic activity was evaluated in a formaldehydeinduced arthritis model in Wistar rats. Treatment with
200 and 400 mg MFE/kg produced significant (apparent
dose-trend) inhibition of the induced arthritis (Table 3).
The mean cumulative arthritic edema measured as the
area under the edema-time curves (AUC) were 1.84 ± 0.57
(15.3% inhibition) and 1.69 ± 0.30 (22.0% inhibition)
for the 200 and 400 mg MFE/kg groups, respectively, as
compared to an AUC of 2.17 ± 0.31 for the negative control group. The maximum inhibition of arthritic edema
(22.0% with 400 mg MFE/kg) was comparable to a 26.9%
inhibition due to 50 mg indomethacin/kg (used as standard anti-arthritic agent) (Table 3).
Viability of AFE-treated BMDM
The toxicity of AFE against the BMDM was determined
using a modification of the MTT cytotoxicity assay. The
results showed that treatment of BMDM with 10–200 µg
AFE/ml did not significantly affect viability.
Table 1. Phytochemical constituents of aqueous and methylene
chloride/methanol extracts of F. exasparata.
Phytoconstituent
MFE
AFE
Carbohydrate
++
+
Alkaloids
++
+
Glycoside
−
++
Saponins
−
++
Tannins
−
−
Flavonoids
+++
++
Resins
++
+
Proteins
+
+
Oil
++
−
Steroids
−
−
Terpenoids
++
++
Acidic compounds
−
+
−, Absent; +, present in low concentration; ++, present in
moderate concentration; +++, abundantly present.
MFE, methylene chloride/methanol extract of F. exasparata; AFE,
Aqueous extract of F. exasparata.
Table 2. Effect of MFE on xylene-induced ear edema in mice.
Treatment
Dose (mg/ear) Edema (mg) Inhibition (%)
—
Vehicle
0
10.00 ± 1.66a
MFE
5.0
7.88 ± 1.46*
21.20
Indomethacin
5.0
4.92 ± 1.03*
50.80
* Value significantly different from vehicle control at p < 0.05.
a
Value is mean ± SE.
Inhibition of LPS-induced IL-1β and TNFα production
in BMDM treated with AFE
High levels of IL-1β and TNFα were measured in culture
supernatants following treatment of the BMDM with 5 µg
LPS/ml; however, pre-treatment of the cells with AFE (5,
25, or 100 µg/ml) significantly inhibited IL-1β and TNFα
formation/release in a concentration-related manner
(Figures 2 and 3) when compared to the cells treated
with LPS alone. Pre-treatment with 5, 25, and 100 µg
AFE/ml resulted in mitigation of LPS-induced TNFα
release from a mean level of 3.52 ± 0.19 ng/ml secreted by
cells treated with LPS alone to 2.00 ± 0.12, 1.32 ± 0.04, and
0.93 ± 0.14 ng/ml, respectively (Figure 2). These reflect
an inhibition of 43.1 ± 3.3, 62.6 ± 2.2, and 73.5 ± 10.4%,
respectively. Pre-treatment AFE also resulted in the
mitigation of LPS-induced IL-1β release from a mean
of 0.50 ± 0.03 ng/ml to 0.31 ± 0.02, 0.21 ± 0.02, and
0.14 ± 0.01 ng/ml, respectively (Figure 3). These reflect
an inhibition of 38.0 ± 4.2, 57.7 ± 3.9, and 73.0 ± 1.70%,
respectively.
Inhibition of LPS-induced NO) release in culture of
BMDM treated with AFE
Expression of inducible nitric oxide (iNO) by macrophages was determined indirectly using Griess reagent.
As shown in Figure 4, the NO concentration in the
medium of LPS-stimulated control cell cultures was
Figure 1. Anti-inflammatory activity of MFE on carrageenaninduced rat paw edema. Rats were randomized in groups (n = 5)
and then treated with MFE (200 or 400 mg/kg, per os), diclofenac
potassium (50 mg/kg, per os), or vehicle. One hour after the drug
administration, agar suspension (2% w/v) was injected into the
sub-plantar surface of each rat hind paw (100 µl/footpad). The
edema produced in the treated paw was measured by the volume
of distilled water displaced by each paw before and 1, 2, 3, 4, and 5 h
after induction of inflammation.
Table 3. Effect of MFE on formaldehyde-induced chronic
inflammation in mice.
Treatment
AUC
Inhibition (%)
Control
2.17 ± 0.31a
—
MFE (200 mg/kg)
1.84 ± 0.57
15.26
MFE (400 mg/kg)
1.69 ± 0.30
22.00*
Indomethacin
1.59 ± 0.13
26.88*
(50 mg/kg)
* Value significantly different from vehicle control at p < 0.05.
a
Value is mean ± SE.
© 2012 Informa Healthcare USA, Inc.
6
C. S. Nworu et al.
significantly higher than those in unstimulated control
wells (31.00 ± 2.08 µM vs 1.900 ± 0.21 µM). This LPSevoked release of iNO was significantly inhibited in a
concentration-dependent manner in BMDM pre-treated
with 5, 25, and 100 µg AFE/ml. AFE pre-treatments
resulted in reductions of NO levels to 24.50 ± 1.32,
19.33 ± 1.16, and 15.67 ± 2.52 µM, respectively. These represents reductions of 20.96, 37.65, and 49.45% compared
to that by cells treated with LPS alone (Figure 4).
Journal of Immunotoxicology Downloaded from informahealthcare.com by Dr Chukwuemeka S. Nworu on 10/27/12
For personal use only.
Discussion
Figure 2. Effect of AFE on LPS-induced TNFα production in vitro.
BMDM were pre-treated with AFE (0, 5, 25, or 100 µg/ml) for 2 h.
The medium was then removed and replaced with fresh medium
and the cells then treated with 10 µg LPS/ml (or medium) for
24 h. The supernatant in each culture well was then collected and
assayed for TNFα via ELISA. Values shown are means (± SE) from
n = 3/treatment group. * Value significantly different (p < 0.05)
compared with that of ‘LPS alone’ control.
Figure 3. Effect of AFE on LPS-induced IL-1β production in vitro.
BMDM were pre-treated with AFE (0, 5, 25, or 100 µg/ml) for 2 h.
The medium was then removed and replaced with fresh medium
and the cells then treated with 10 µg LPS/ml (or medium) for
24 h. The supernatant in each culture well was then collected and
assayed for IL-1β via ELISA. Values shown are means (± SE) from
n = 3/treatment group. * Value significantly different (p < 0.05)
compared with that of ‘LPS alone’ control.
Inflammation is fundamentally a protective response
and is ultimately aimed at ridding the organism of both
the initial cause of cell injury (e.g., microbes, toxins)
and the sequelae of such injury (e.g., necrotic cells and
tissues). Inflammation is terminated when the offending agent is eliminated and the secreted mediators are
broken down or dissipated. In addition, there are innate
anti-inflammatory mechanisms that serve to control the
response and prevent it from causing excessive damage
to the host. When these counter-regulatory mechanisms
fail or are overwhelmed by the offending agents, an
inflammatory disease supervenes (Cotran et al., 1998;
Abbas and Lichtman, 2011). Inflammatory diseases,
such as rheumatism and arthritis, have continued to be a
significant cause of debilitation, morbidity, and mortality
globally. Since the discovery of acetylsalicylic acid (aspirin) from the bark of the Willow plant (Salixalba) more
than 100 years ago, many other non-steroidal as well as
steroidal anti-inflammatory drugs have been introduced
for clinical management of inflammatory disorders.
However, the prolonged use of most of these medications is associated with some unwanted and often serious side-effects, mainly renal problems, gastrointestinal
Figure 4. Effect of AFE on inducible (iNO) production. Effect of AFE
on LPS-induced NO production. BMDM were pre-treated with AFE
(0, 5, 25, 100 µg/ml) for 2 h. The medium was then removed and
replaced with fresh medium and the cells then treated with 10 µg
LPS/ml (or medium) for 24 h. The supernatant in each culture well
was then collected for and assayed for NO using a Griess reagent
protocol. Values shown are means (± SE) from n = 3/treatment
group. * Value significantly different (p < 0.05) compared with that
of ‘LPS alone’ control.
Journal of Immunotoxicology
Journal of Immunotoxicology Downloaded from informahealthcare.com by Dr Chukwuemeka S. Nworu on 10/27/12
For personal use only.
Anti-inflammatory mechanisms of F. exasperata leaf extracts 7
irritation, and ulcerations (Bertolini et al., 2001; Green,
2001). Therefore, there is still an unmet need of discovering potent anti-inflammatory molecules that are devoid
of the limitations of the present therapeutic options. This
has encouraged more research on medicinal plants that
are used in complementary and traditionally medicine
for the treatment pains, fever, and rheumatic pains (Basu
and Hazra, 2006).
The study reported here investigated the anti-inflammatory activities and mechanisms of Ficus exasperata
leaf extracts. The leaf and stalk of F. exasperata are used by
the Igede people of Nigeria to mitigate itching or inflammation, and are prepared as poultices that are applied to
swellings/arthritic joints. The beneficial claims in these
traditional practices inspired this study in which topical and systemic (acute and chronic) anti-inflammatory
activities of the extracts were studied in rodents. Because
increased expression and release of pro-inflammatory
cytokines and mediators are involved in inflammatory
processes, the study included experiments to assess
effects of the extracts on inducible IL-1β, TNFα, and iNO
formation/release by cultured macrophages.
The results show that MFE significantly inhibited acute
inflammation in vivo. Rats pre-treated with MFE showed
significant increases in remission of edema induced by
agar. This data supports the results of a recent study in
which a hydroalcoholic leaf extract of F. exasperata was
evaluated for anti-nociceptive, anti-inflammatory, and
anti-pyretic properties in chicks (Woode et al., 2009). That
study reported that the leaf extract (given at 10–300 mg/kg
per os) yielded a dose-dependent anti-inflammatory activity against carrageenan-induced footpad edema, with an
IC50 of ≈ 46 mg/kg. Acute inflammation induced by xylene
was also inhibited in mice by topical application of MFE.
The method of xylene-inducible ear edema has some
advantages in natural product testing, including a good
predictive value for the screening of anti-inflammatory
agents. Xylene causes an instant irritation of the ear that
leads to fluid accumulation/edema characteristic of an
acute inflammatory response; suppression of this response
is indicative of an anti-phlogistic effect. The eventual
increase in ear weight and inflammation seen in this model
is due to neutrophil accumulation. This cellular influx plays
a critical role in cutaneous inflammatory diseases like dermatitis, and is related to the pathological mechanism of the
disease (Bradley et al., 1982).
Inhibition of formaldehyde-induced pedal edema in
rats has been reported, and is often used, as a suitable
model to assess potential anti-arthritic/-inflammatory
agents. The model is believed to closely resemble human
arthritis (Greenward, 1991). It is also remarkable that
daily administration of MFE (200 and 400 mg/kg) for
10 days decreased formaldehyde-induced arthritis (a
manifestation of chronic inflammatory processes) in
the test rats. This outcome is also akin to that in a recent
report that showed that the administration of an ethanolic F. exasperata leaf extract (given at 30–300 mg/kg,
per os) significantly reduced Freund’s adjuvant-induced
arthritic edema in the ipsilateral paw of rats (with a maximal inhibition of ≈ 34%) and also prevented the spread of
edema from the ipsilateral to contralateral paw, indicating inhibition of systemic spread (Abotsi et al., 2010).
The results of the in vitro studies showed that pre-treatment of bone marrow derived macrophages with AFE led
to a concentration-dependent suppression of the formation/release of IL-1β, TNFα, and iNO. Unregulated levels
of pro-inflammatory cytokines have been implicated as a
potential etiological factor in the development of several
acute and chronic inflammatory diseases (Esposito and
Giugliano, 1994; Ohshima and Bartsch, 1994; Krakauer,
2004). LPS is a potent inducer of inflammatory agents
in macrophages; as such, LPS stimulation is frequently
used to evaluate the efficacy of potential drugs/products against inflammatory response (Hong et al., 2009;
Pearson et al., 2010). Based on the findings here, the inhibition of inducible IL-1β, TNFα, and iNO production by
the extracts of F. exasperata could explain, at least in part,
the anti-inflammatory activities of the plant reported in
the two edema models here and, more importantly, in
the outcomes ascribed to their ethno-medicinal use.
While NO is critical in host defense against microorganisms and tumor cells, excess NO production is
associated with several inflammatory diseases, e.g.,
arthritis, autoimmune diseases, septic shock. In these
disorders, NO contributes to the inflammatory cascade
by increasing vascular permeability and extravasation of
fluid/proteins at sites of inflammation (Moncada et al.,
1991; Snyder and Bredt, 1992; Guzik et al., 2003). NO is
produced by NO synthase (NOS) (Korhonen et al., 2005);
after exposure to LPS, iNOS is quantitatively induced in
macrophages (Duval et al., 1996). As such, inhibition of
NO production has been a therapeutic strategy increasingly used in the treatment of various inflammatory diseases. This may also be a contributing factor underlying
the observed anti-inflammatory activities of MFE.
The inhibitory effects of AFE on IL-1β, TNFα, and iNO
formation/release by the BMDM were not due to cytotoxicity. Viability of these macrophages was not affected
by AFE at the concentrations used in the in vitro studies. Similarly, the acute toxicity studies in mice did not
suggest severe untoward effects after oral and intraperitoneal administrations at doses up to 5000 mg MFE/kg
(Lorke, 1983).
Preliminary phytochemical studies showed that the
extracts are rich in flavonoids, terpenoids, and alkaloids
among other constituents. Although the study has not
associated any of these constituents with the activities
recorded, some of these bioactive constituents have been
reported in previous studies to inhibit inflammation and
suppress the production and release of pro-inflammatory
mediators by monocytic cells. For examples, plant terpenoids have been reported to possess anti-inflammatory
activities (Calou et al., 2008; Salinas-Sánchez et al.,
2012; Zhang et al., 2012). Plant alkaloids have also been
reported, in previous studies, to suppress inflammatory
responses in rodents (Chakraborty and Brantner, 2001).
© 2012 Informa Healthcare USA, Inc.
Journal of Immunotoxicology Downloaded from informahealthcare.com by Dr Chukwuemeka S. Nworu on 10/27/12
For personal use only.
8
C. S. Nworu et al.
Similarly, many studies have shown that plant flavonoids possess anti-inflammatory activities in vitro and
in cellular models which involve the inhibition of the
expression and actions of different pro-inflammatory
mediators such as eicosanoids, cytokines, adhesion molecules, and C-reactive protein (Hämäläinen et al., 2007;
Serafini et al., 2010). Prostaglandins and nitric oxide
biosynthesis are involved in inflammation, and isoforms
of inducible nitric oxide synthase (iNOS) and of cyclooxygenase (COX-2) are responsible for the production
of a great amount of inflammatory mediators. It has also
been demonstrated that flavonoids are able to inhibit
both enzymes (Marcinkiewicz, 1997; Chen et al., 2001;
Shen et al., 2002). Flavonoids modulate the cascade of
molecular events leading to the over-expression of these
mediators which include inhibition of the transcription
factors such as nuclear factor-κB (NFκB) and activating protein-1 (AP-1), through the inhibition of protein
kinases involved in signal transduction (GonzálezGallego et al., 2007; Tuñón et al., 2009).
Conclusion
In summary, the results of the various investigations show
that F. exasperata leaf extracts possess anti-inflammatory
properties that could underlie the benefits associated
with the folklore use of the plant. The results also show
that the extracts may be acting through the suppression of
mediators of inflammation such as IL-1β, TNFα, and iNO.
This means that F. exasperata should be explored further
as a potential source of anti-inflammatory compounds.
Declaration of Interest
The authors report no conflicts of interest. The authors
alone are responsible for the content and writing of the
paper.
References
Abbas, A. B., and Lichtman, A. H. (Eds.) 2011. Innate immunity. In:
Basic Immunology. Functions and disorders of the immune system
(3rd Edition). Philadelphia, PA: Saunders Elsevier, pp. 23–44.
Abotsi, W. M., Woode, E., Ainooson, G. K., Amo-Barimah, A. K., and
Boakye-Gyasi, E. 2010. Anti-arthritic and antioxidant effects of
the leaf extract of Ficus exasperata P. Beauv. Pharmacognosy Res.
2:89–97.
Ahmed, M. M., Qureshi, S., Al-bekairi, A. M., Shah, A. H., Rao, R.
M., Qazi, N. S. 1993. Anti-inflammatory Activity of Caralluma
tuberculata alcoholic extract. Fitoterapia 64:359–362.
Akah, P. A., and Nwambie, A. I. 1994. Evaluation of Nigerian traditional
medicines: Plants used for rheumatic disorder. J. Ethnopharmacol.
42:179–182.
Akah, P. A., Gamaniel, K. S., Nwambebe, C. O., Shittu, A., Kapu, S. D.,
and Kunle, O. O. 1997. Studies on the gastrointestinal properties of
Ficus exaparata. Fitoterapia 89:17–20.
Akah, P. A., Orisakwe, O.E., Gamaniel, K.S., Shittu, A. 1998. Evaluation
of Nigerian traditional medicines: II. Effects of some Nigerian folk
remedies on peptic ulcer. J. Ethnopharmacol. 62(2):123–127.
Asuzu, I. U., Sosa, S., and Della, L. R. 1999. The anti-inflammatory
activity of Icacina trichantha tuber. Phytomedicine 6:267–272.
Atta, A. H., and Alkohafi, A. 1998. Anti-nociceptive and antiinflammatory effects of some Jordanian medicinal plants extracts.
J. Ethnopharmacol. 60:117–124.
Ayinde, B. A., Omogbai, E. K., and Amaechina, F. C. 2007.
Pharmacognosy and hypotensive evaluation of Ficus exasperata
Vahl (Moraceae) leaf. Acta Pol. Pharm. 64:543–546.
Ayoola, G. A., Akpanika, G. A., Awobajo, F. O., Sofidiya, M. O., Osunkalu,
V. O., Coker, H. A., and Odugbemi, T. O. 2009. Anti-inflammatory
properties of the fruits of Allanblanckia floribunda oliv (Guttiferae).
Bot. Res. Intl. 2:21–26.
Backhouse, N., Delporte, C., Negrete, R., Salinus, P., Pinto, A., Aravena,
S., and Cassels, B. K. 1996. Anti-inflammatory and antipyretic
activities of Cuscuta chilensis, Cestrum parqui, and Psolarea
glandulosa. Int. J. Pharmacog. 34:53–57.
Basu, S., and Hazra, B. 2006. Evaluation of nitric oxide scavenging activity,
in vitro and ex vivo, of selected medicinal plants traditionally used
in inflammatory diseases. Phytother. Res. 20:896–900.
Bertolini, A., Ottani, A., and Sandrini, M. 2001. Dual acting antiinflammatory drugs: A reappraisal. Pharmacol. Res. 44:437–450.
Bradley, P. P., Priebat, D. A., Christensen, R. D., and Rothstein, G.
1982. Measurement of cutaneous inflammation: Estimation of
neutrophil content with an enzyme marker. J. Invest. Dermatol.
78:206–209.
Calou, I. B., Sousa, D. I., Cunha, G. M., Brito, G. A., Silveira, E. R., Rao,
V. S., and Santos, F. A. 2008. Topically applied diterpenoids from
Egletes viscosa (Asteraceae) attenuate dermal inflammation in
mouse ear induced by tetradecanoylphorbol-13-acetate and
oxazolone. Biol. Pharm Bull. 31:1511–1516.
Chakraborty, A., and Brantner, A. H. 2001. Study of alkaloids from
Adhatoda vasica Nees on their anti-inflammatory activity.
Phytother. Res. 15:532–534.
Chen, Y. C., Shen, S. C., Lee, W. R., Hou, W. C., Yang, L. L., and Lee,
T. J. 2001. Inhibition of nitric oxide synthase inhibitors and
lipopolysaccharide induced inducible NOS and cyclooxygenase-2
gene expressions by rutin, quercetin, and quercetin pentaacetate
in RAW 264.7 macrophages. J. Cell. Biochem. 82:537–548.
Chhabra, S. C., Mahunnah, R. L., and Mshiu, E. N. 1990. Plants used
in traditional medicine in Eastern Tanzania. IV. Angiosperms
(Mimosaceae to Papilionaceae). J. Ethnopharmacol. 29:295–323.
Cotran, R. S., Kumar, V., and Collins, T. (Eds.). 1998. Robbins Pathologic
Basis of Disease. Philadelphia, PA: W.B Saunders Company.
Duval, D. L., Miller, D. R., Collier, J., and Billings, R. E. 1996.
Characterization of hepatic nitric oxide synthase: Identification as
the cytokine-inducible form primarily regulated by oxidants. Mol.
Pharmacol. 50:277–284.
Esposito, K., and Giugliano, D. 1994. The metabolic syndrome and
inflammation, association or causation? Nutr. Metab. Cardiovasc.
Dis. 14:228–232.
Evans, W. C. (Ed.). 1998. Trease and Evans Pharmacognosy. (14th
Edition). New York: WB Saunders Company Ltd, pp. 15–16.
Fereidoni, M., Ahmadiani, A., Semnanian, S., and Javan, M, 2000. An
accurate and simple method for measurement of paw edema. J.
Pharmacol. Toxicol. Meth. 43:11–14.
Gad, S. C., Dobbs, D. W., Dunn, B. J., Reilly, C., Walsh, R. D., Auletta,
C. S., Hile, R. A., Reagan, E., and Yenser, B. 1987. Inter-laboratory
validation test (MEST). In: In Vitro Toxicology - Approaches to
Validation (Goldberg, A. M., Ed.). New York: Liebert, pp. 275–292.
González-Gallego, J., Sánchez-Campos, S., and Tuñón, M. J. 2007.
Anti-inflammatory properties of dietary flavonoids. Nutr. Hosp.
22:287–293.
Green, G. A. 2001. Understanding NSAIDs: From aspirin to COX-2. Clin.
Cornerstone 3:50–60.
Greenward, R. A. 1991. Animal models for evolution of arthritic drugs.
Meth. Find. Exp. Clin. Pharmacol. 13:75–83.
Guzik, T. J., Korbut, R., and Adamek-Guzik, T. 2003. Nitric oxide and
superoxide in inflammation and immune regulation. J. Physiol.
Pharmacol. 54:469–487.
Hämäläinen, M., Nieminen, R., Vuorela, P., Heinonen, M., and
Moilanen, E. 2007. Anti-inflammatory effects of flavonoids:
Journal of Immunotoxicology
Journal of Immunotoxicology Downloaded from informahealthcare.com by Dr Chukwuemeka S. Nworu on 10/27/12
For personal use only.
Anti-inflammatory mechanisms of F. exasperata leaf extracts 9
Genistein, kaempferol, quercetin, and daidzein inhibit STAT-1 and
NF-κB activations, whereas flavone, isorhamnetin, naringenin,
and pelargonidin inhibit only NF-κB activation along with their
inhibitory effect on iNOS expression and NO production in
activated macrophages. Med. Inflamm. 2007:45673.
Harborne, J. B., and Harborne, A. J. (Eds.). 1998. Phytochemical
Methods: A Guide to Modern Techniques of Plant Analysis. London:
Kluwer Academic Publishers.
Hong, Y. H., Chao, W. W., Chen, M. L., and Lin, B. F. 2009. Ethyl
acetate extracts of alfalfa (Medicago sativa L.) sprouts inhibit
lipopolysaccharide-induced inflammation in vitro and in vivo. J.
Biomed. Sci. 16:64.
Igoli, J. O., Ogaji, O. G., Tor-Anyiin, T. A., and Igoli, N. P. 2005. Traditional
medicine practice amongs the Igede People of Nigeria. PART II.
Afr. J. Trad. CAM 2:134–152.
Irvine, F. R. 1961. Woody plants of Ghana. 1st edition. London: Oxford
University Press.
Korhonen, R., Lahti, A., Kankaanranta, H., and Moilanen, E. 2005.
Nitric oxide production and signaling in inflammation. Curr. Drug
Targets Inflamm. Allergy 4:471–479.
Krakauer, T. 2004. Molecular therapeutic targets in inflammation,
cyclooxygenase and NF-κB. Curr. Drug Targets 3:317–324.
Lin, H., Chen, C., and Chen, B. D. 2001. Resistance of bone marrowderived macrophages to apoptosis is associated with the
expression of X-linked inhibitor of apoptosis protein in primary
cultures of bone marrow cells. Biochem. J. 353:299–306.
Lorke, D. 1983. A new approach to practical acute toxicity testing. Arch.
Toxicol. 53:275–289.
Marcinkiewicz, J. 1997. Regulation of cytokine production by
eicosanoids and nitric oxide. Arch. Immunol. Ther. Exp. (Warsz)
45:163–167.
Moncada, S., Palmer, R. M., and Higgs, E. A. 1991. Nitric oxide:
Physiology, pathophysiology, and pharmacology. Pharmacol. Rev.
43:109–142.
Mosmann, T. 1983. Rapid colorimetric assay for cellular growth and
survival: Application to proliferation and cytotoxicity assays. J.
Immunol. Meth. 65:55–63.
Ohshima, H., and Bartsch, H. 1994. Chronic infections and inflammatory
processes as cancer risk factors, possible role of nitric oxide in
carcinogenesis. Mutat. Res. 305:253–264.
Pearson, W., Fletcher, R. S., Kott, L. S., and Hurtig, M. B. 2010. Protection
against LPS-induced cartilage inflammation and degradation
provided by a biological extract of Mentha spicata. BMC
Complement. Altern. Med. 10:19.
Perez, F., Marin, E., Adzet, T. 1995. The anti-inflammatory effect of several
Compositae from South America extracts in rats. Phytother. Res.
9:145–146.
Perianayagam, J. B., Sharma, S. K., and Pillai, K. K. 2006. Antiinflammatory activity of Trichodesma indicum root extract in
experimental animals. J. Ethnopharmacol. 104:410–414.
Salinas-Sánchez, D. O., Herrera-Ruiz, M., Pérez, S., JiménezFerrer, E., and Zamilpa, A. 2012. Anti-inflammatory activity of
hautriwaic acid isolated from Dodonaea viscosa leaves. Molecules
17:4292–4299.
Selye, H. 1949. Further studies concerning the participation of
the adrenal cortex in the pathogenesis of arthritis. Br. Med. J.
2:1129–1135.
Serafini, M., Peluso, I., and Raguzzini, A. 2010. Flavonoids as antiinflammatory agents. Proc. Nutr. Soc. 69:273–278.
Shen, S. C., Lee, W. R., Lin, H., Huang, H. C., Ko, C. H., Yang, L. L.,
and Chen, Y. C. 2002. In vitro and in vivo inhibitory activities of
rutin, wogonin, and quercetin on lipopolysaccharide-induced
nitric oxide and prostaglandin E2 production. Eur. J. Pharmacol.
446:187–194.
Snyder, S. H., and Bredt, D. S. 1992. Biological roles of nitric oxide. Sci.
Am. 266:68–71.
Tubaro, A., Dri, P., Delbello, G., Zilli, C., and Della, L. R. 1985. The croton
oil ear test revisited. Agents Actions 17:347–349.
Tuñón, M. J., García-Mediavilla, M. V., Sánchez-Campos, S., and GonzálezGallego, J. 2009. Potential of flavonoids as anti-inflammatory agents:
Modulation of pro-inflammatory gene expression and signal
transduction pathways. Curr. Drug Metab. 10:256–271.
Vane, J. R., and Bolting, R. M. 1995. New insights into the mode of action
of anti- inflammatory drugs. Inflammation Res. 44:1–10.
Weischenfeldt, J., and Porse, B. 2008. Bone marrow-derived
macrophages (BMM): Isolation and applications. Available online
at: http://cshprotocols.cshlp.org/cgi/content/full/2008/13/pdb.
prot5080. (Cold Spring Harbor Protocols).
Winter, C. A., Risley, E. A., Nuss, G. W. 1962. Carrageenin-induced
edema in the hind paw of the rat as an assay for anti-inflammatory
drugs. Proc. Soc. Exp. Biol. Med. 3:544–547.
Woode, E., Poku, R. A., Ainooson, G. K., Boakye-Gyasi, E., Abotsi, W. K.,
Mensah, T. L., and Amoh-Barimah, A. K. 2009. An evaluation of the
anti-inflammatory, antipyretic, and antinociceptive effects of Ficus
exasperata (Vahl) leaf extract. J. Pharmacol. Toxicol. 4:138–151.
Zhang, F., Wang, J. S., Gu, Y. C., Kong, L. Y. 2012. Cytotoxic and antiinflammatory triterpenoids from Toona ciliata. J. Nat. Prod.
75:538–546.
© 2012 Informa Healthcare USA, Inc.
View publication stats